Reactogenicity of COVID-19 Vaccines; Insights from Cairo University Hospitals | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 338, Volume 90, Issue 2, January 2023, Page 3753-3763 PDF (748 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.293438 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Since the emergence of the COVID-19 pandemic, most of the efforts were directed towards developing new vaccines that are safe and effective to terminate the pandemic. Methods :This is a cross-sectional study, to analyze the short-term side effect profile of the AstraZeneca/Oxford vaccine and Sinopharm Chinese vaccine. A quantitative survey using Google Forms was used for healthcare workers at Cairo University Hospitals from February to May 2021. From total of 4962 healthcare workers who received COVID-19 vaccines through this period, 1190 responded to the questionnaire. The collected data included side effects, duration, and symptoms’ severity. Results: Around 50% and 20% of the participants did not report any symptoms after Sinopharm and AstraZeneca vaccines, respectively. Participants receiving AstraZeneca vaccine were 3.6 times more likely to have fever compared to those receiving Sinopharm [OR (95%CI) 3.62 (2.18-6.04)]. Also, they were more likely to have mild, moderate, and severe local reaction in comparison with those receiving Sinopharm [OR (95%CI) 2.01 (1.46-2.78), 6.13 (3.29-11.40), and 6.06 (1.07-34.33), respectively]. The duration of symptoms of both vaccines did not differ. Conclusion: While both vaccines were safe, the healthcare workers who received Sinopharm vaccine showed significantly fewer side effects compared to AstraZeneca recipients. | ||||
| Keywords | ||||
| Astrazeneca; Covid-19; Side Effects; Sinopharm; Vaccination | ||||
|
Statistics Article View: 125 PDF Download: 176 |
||||
